These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 39242413

  • 1. Treatment-related hearing loss in weekly versus triweekly cisplatin chemoradiation for head and neck cancer.
    Burger AVM, Duinkerken CW, van Sluis KE, de Boer JP, Navran A, Lanting CP, Jóźwiak K, Dreschler WA, Balm AJM, Zuur CL.
    Eur Arch Otorhinolaryngol; 2024 Sep 06. PubMed ID: 39242413
    [Abstract] [Full Text] [Related]

  • 2. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
    Zuur CL, Simis YJ, Lansdaal PE, Hart AA, Schornagel JH, Dreschler WA, Rasch CR, Balm AJ.
    J Clin Oncol; 2007 Aug 20; 25(24):3759-65. PubMed ID: 17704425
    [Abstract] [Full Text] [Related]

  • 3. Long-term hearing loss after chemoradiation in patients with head and neck cancer.
    Theunissen EA, Zuur CL, Bosma SC, Lopez-Yurda M, Hauptmann M, van der Baan S, de Boer JP, van der Molen L, Rasch CR, Dreschler WA, Balm AJ.
    Laryngoscope; 2014 Dec 20; 124(12):2720-5. PubMed ID: 24964759
    [Abstract] [Full Text] [Related]

  • 4. Audiological Outcomes of Weekly vs. Triweekly Cisplatin in Head and Neck Cancer with Cochlear-Sparing Intensity-Modulated Radiation Therapy.
    Gamez ME, Blakaj DM, Bhateja P, Custer A, Klamer BG, Pan J, Gogineni E, Baliga S, Bonomi MR.
    Cancers (Basel); 2024 Jun 14; 16(12):. PubMed ID: 38927933
    [Abstract] [Full Text] [Related]

  • 5. Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis.
    Mohamed A, Twardy B, Zordok MA, Ashraf K, Alkhoder A, Schrapp K, Steuer C, Chen Z, Pakkala S, Pillai R, Trad Wadsworth J, Higgins K, Beitler JJ, Ramalingam SS, Owonikoko TK, Khuri FR, Shin DM, Behera M, Saba NF.
    Head Neck; 2019 May 14; 41(5):1490-1498. PubMed ID: 30835900
    [Abstract] [Full Text] [Related]

  • 6. Comparison of radiation and chemoradiation-induced sensorineural hearing loss in head and neck cancer patients.
    Mahdavi SR, Rezaeyan A, Nikoofar A, Bakhshandeh M, Farahani S, Cheraghi S.
    J Cancer Res Ther; 2020 May 14; 16(3):539-545. PubMed ID: 32719264
    [Abstract] [Full Text] [Related]

  • 7. Hearing and tinnitus in head and neck cancer patients after chemoradiotherapy.
    Niemensivu R, Saarilahti K, Ylikoski J, Aarnisalo A, Mäkitie AA.
    Eur Arch Otorhinolaryngol; 2016 Sep 14; 273(9):2509-14. PubMed ID: 26685859
    [Abstract] [Full Text] [Related]

  • 8. Hearing loss due to concurrent daily low-dose cisplatin chemoradiation for locally advanced head and neck cancer.
    Zuur CL, Simis YJ, Verkaik RS, Schornagel JH, Balm AJ, Dreschler WA, Rasch CR.
    Radiother Oncol; 2008 Oct 14; 89(1):38-43. PubMed ID: 18706728
    [Abstract] [Full Text] [Related]

  • 9. The association between skeletal muscle mass and sensorineural hearing loss upon cisplatin-based chemoradiotherapy in patients with head and neck squamous cell carcinoma.
    Schaeffers AWMA, Burger AVM, Duinkerken CW, van Sluis KE, de Boer JP, van der Molen L, Hoetink AE, Al-Mamgani A, Jóźwiak K, Devriese LA, de Bree R, Zuur CL.
    Head Neck; 2024 Aug 02. PubMed ID: 39096016
    [Abstract] [Full Text] [Related]

  • 10. The evidence on effectiveness of weekly vs triweekly cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC): a systematic review and meta-analysis.
    Jacinto JK, Co J, Mejia MB, Regala EE.
    Br J Radiol; 2017 Nov 02; 90(1079):20170442. PubMed ID: 29053029
    [Abstract] [Full Text] [Related]

  • 11. A randomized controlled trial to test the efficacy of trans-tympanic injections of a sodium thiosulfate gel to prevent cisplatin-induced ototoxicity in patients with head and neck cancer.
    Rolland V, Meyer F, Guitton MJ, Bussières R, Philippon D, Bairati I, Leclerc M, Côté M.
    J Otolaryngol Head Neck Surg; 2019 Jan 16; 48(1):4. PubMed ID: 30651130
    [Abstract] [Full Text] [Related]

  • 12. A new grading system for ototoxicity in adults.
    Theunissen EA, Dreschler WA, Latenstein MN, Rasch CR, van der Baan S, de Boer JP, Balm AJ, Zuur CL.
    Ann Otol Rhinol Laryngol; 2014 Oct 16; 123(10):711-8. PubMed ID: 24820112
    [Abstract] [Full Text] [Related]

  • 13. Protective effects of sodium thiosulfate for cisplatin-mediated ototoxicity in patients with head and neck cancer.
    Ishikawa E, Sugimoto H, Hatano M, Nakanishi Y, Tsuji A, Endo K, Kondo S, Wakisaka N, Murono S, Ito M, Yoshizaki T.
    Acta Otolaryngol; 2015 Sep 16; 135(9):919-24. PubMed ID: 25861690
    [Abstract] [Full Text] [Related]

  • 14. Clinical Predictors of Cisplatin Chemoradiation-Induced Ototoxicity in HPV-Positive Oropharyngeal Squamous Cell Carcinoma: A Case-Control Study.
    Lee JJ, Alamleh S, Zhan LJ, Hueniken K, Mahler MB, Billfalk-Kelly A, Davies J, Brown MC, Spreafico A, Huang SH, Hope A, Xu W, Goldstein DP, Liu G.
    J Otolaryngol Head Neck Surg; 2024 Sep 16; 53():19160216241248671. PubMed ID: 39056507
    [Abstract] [Full Text] [Related]

  • 15. Prediction of Hearing Loss Due to Cisplatin Chemoradiotherapy.
    Theunissen EA, Zuur CL, Józwiak K, Lopez-Yurda M, Hauptmann M, Rasch CR, van der Baan S, de Boer JP, Dreschler WA, Balm AJ.
    JAMA Otolaryngol Head Neck Surg; 2015 Sep 16; 141(9):810-5. PubMed ID: 26291150
    [Abstract] [Full Text] [Related]

  • 16. Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer.
    Madasu R, Ruckenstein MJ, Leake F, Steere E, Robbins KT.
    Arch Otolaryngol Head Neck Surg; 1997 Sep 16; 123(9):978-81. PubMed ID: 9305250
    [Abstract] [Full Text] [Related]

  • 17. Weekly cisplatin chemotherapy dosing versus triweekly chemotherapy with concurrent radiation for head and neck squamous cell carcinoma.
    Morse RT, Ganju RG, TenNapel MJ, Neupane P, Kakarala K, Shnayder Y, Chen AM, Lominska CE.
    Head Neck; 2019 Aug 16; 41(8):2492-2499. PubMed ID: 30856297
    [Abstract] [Full Text] [Related]

  • 18. Weekly cisplatin therapy compared with triweekly combination chemotherapy as concurrent adjuvant chemoradiation therapy after radical hysterectomy for cervical cancer.
    Lee HN, Lee KH, Lee DW, Lee YS, Park EK, Park JS.
    Int J Gynecol Cancer; 2011 Jan 16; 21(1):128-36. PubMed ID: 21330837
    [Abstract] [Full Text] [Related]

  • 19. Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin.
    van der Vorst MJDL, Neefjes ECW, Toffoli EC, Oosterling-Jansen JEW, Vergeer MR, Leemans CR, Kooistra MP, Voortman J, Verheul HMW.
    BMC Cancer; 2019 Nov 08; 19(1):1066. PubMed ID: 31703649
    [Abstract] [Full Text] [Related]

  • 20. Predicting Hearing Loss After Radiotherapy and Cisplatin Chemotherapy in Patients With Head and Neck Cancer.
    Schuette A, Lander DP, Kallogjeri D, Collopy C, Goddu S, Wildes TM, Daly M, Piccirillo JF.
    JAMA Otolaryngol Head Neck Surg; 2020 Feb 01; 146(2):106-112. PubMed ID: 31750863
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.